Table 1 Patient Characteristics in Cavitary and Noncavitary Adenocarcinoma with EGFR mutations

Age, Median (range), y

61 (26–86)

61 (37–76)

61 (26–86)

0.271

 ≤65

178 (64.5)

12 (80.0)

166 (63.6)

 > 65

98 (35.5)

3 (20.0)

95 (36.4)

Gender, no. (%)

0.008

 Male

96 (34.8)

10 (66.7)

86 (33.0)

 Female

108 (65.2)

5 (33.3)

175 (67.0)

Smoking history, no. (%)

0.494

 Nonsmokers

224 (81.2)

11 (73.3)

213 (81.6)

 Former or current smokers

52 (18.8)

4 (26.7)

48 (18.4)

ECOG PS, no. (%)

0.377^a

 0

10 (3.6)

1 (6.7)

9 (3.4)

 1

242 (87.7)

14 (93.3)

228 (87.4)

 2

20 (7.2)

0 (0.0)

20 (7.7)

 3

4 (1.4)

0 (0.0)

4 (1.5)

TNM stage, no. (%)

0.478^b

 Recurrent

14 (5.1)

1 (6.7)

13 (5.0)

 IIIB

31 (11.2)

0 (0.0)

31 (11.9)

 IV

231 (83.7)

14 (93.3)

217 (83.1)

T stage, no. (%)

0.270

 T1–2

101 (36.6)

5(33.3)

96 (36.8)

 T3–4

175 (63.4)

10 (66.7)

165 (63.2)

N stage, no. (%)

0.532

 N0–1

64 (23.2)

2 (13.3)

62 (23.8)

 N2–3

212 (76.8)

13 (86.7)

199 (76.2)

Mean tumor size (cm), ±SD

3.73 ± 1.74

2.87 ± 0.99

3.76 ± 1.76

0.056

Brain metastasis, no. (%)

71 (25.7)

4 (26.7)

67 (25.7)

1.000

Liver metastasis, no. (%)

17 (6.2)

1 (6.7)

16 (6.1)

1.000

Bone metastasis, no. (%)

116 (42.0)

8 (53.3)

108 (41.4)

0.362

EGFR-TKI, no. (%)

0.537^c

 Gefitinib

185 (67.0)

9 (60.0)

176 (67.4)

 Erlotinib

45 (16.3)

2 (13.3)

43 (16.5)

 Icotinib

44 (15.9)

4 (26.7)

40 (15.3)

 Afatinib/Osimertinib

2 (0.8)

0 (0.0)

2 (0.8)

EGFR mutations, no. (%)

0.362^d

 Exon 19 deletion

117 (42.4)

9 (60.0)

108 (41.4)

 L858R mutation

130 (47.1)

6 (40.0)

124 (47.5)

 Rare^e

29 (10.5)

0 (0.0)

29 (11.1)